{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:49Z","timestamp":1787032849350,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,30]]},"DOI":"10.7759\/cureus.11252","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T05:20:02Z","timestamp":1604035202000},"source":"Crossref","is-referenced-by-count":3,"title":["Severe Pancytopenia Induced by Valproic Acid"],"prefix":"10.7759","author":[{"given":"Andrew","family":"Wahba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmalee","family":"Bergez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca E","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002, 16:695-714. 10.2165\/00023210-200216100-00004","journal-title":"CNS Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher W","year":"2002","unstructured":"L\u00f6scher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002, 16:669-94. 10.2165\/00023210-200216100-00003","journal-title":"CNS Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"4","author":"Ghodke-Puranik Y","year":"2013","unstructured":"Ghodke-Puranik Y, Thorn CF, Lamba JK, et al.. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013, 4:236-41. 10.1097\/FPC.0b013e32835ea0b2","journal-title":"Pharmacogenet Genomics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626120-00002","article-title":"Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER","volume":"26","author":"Dutta S","year":"2006","unstructured":"Dutta S, Reed RC. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER. Clin Drug Investig. 2006, 26:681-90. 10.2165\/00044011-200626120-00002","journal-title":"Clin Drug Investig"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011428138","article-title":"Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients","volume":"52","author":"Williams JH","year":"2012","unstructured":"Williams JH, Jayaraman B, Swoboda KJ, Barrett JS. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. J Clin Pharmacol. 2012, 52:1676-88. 10.1177\/0091270011428138","journal-title":"J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200608020-00004","article-title":"Valproate as a mainstay of therapy for pediatric epilepsy","volume":"8","author":"Guerrini R","year":"2006","unstructured":"Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs. 2006, 8:113-29. 10.2165\/00148581-200608020-00004","journal-title":"Paediatr Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.078568","article-title":"Altered function of the SCN1A voltage-gated sodium channel leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities","volume":"26","author":"Martin MS","year":"2010","unstructured":"Martin MS, Dutt K, Papale LA, et al.. Altered function of the SCN1A voltage-gated sodium channel leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities. J Biol Chem. 2010, 26:9823-34. 10.1074\/jbc.M109.078568","journal-title":"J Biol Chem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02640.x","article-title":"Sodium channel SCN1A and epilepsy: mutations and mechanisms","volume":"51","author":"Escayg A","year":"2010","unstructured":"Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia. 2010, 51:1650-8. 10.1111\/j.1528-1167.2010.02640.x","journal-title":"Epilepsia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/cc3742","article-title":"Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?","volume":"5","author":"Lheureux PE","year":"2005","unstructured":"Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?. Crit Care. 2005, 5:431-40. 10.1186\/cc3742","journal-title":"Crit Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01429.x","article-title":"Valproate-induced thrombocytopenia: a prospective monotherapy study","volume":"49","author":"Nasreddine W","year":"2008","unstructured":"Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008, 49:438-45. 10.1111\/j.1528-1167.2007.01429.x","journal-title":"Epilepsia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0224-6","article-title":"The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data","volume":"18","author":"Buoli M","year":"2018","unstructured":"Buoli M, Serati M, Botturi A, Altamura AC. The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data. Drugs RD. 2018, 18:1-5. 10.1007\/s40268-017-0224-6","journal-title":"Drugs RD"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(96)00052-5","article-title":"Valproic acid and thrombocytopenia in children: a case-controlled retrospective study","volume":"14","author":"Allarakhia IN","year":"1996","unstructured":"Allarakhia IN, Garofalo EA, Komarynski MA, Robertson PL. Valproic acid and thrombocytopenia in children: a case-controlled retrospective study. Pediatr Neurol. 1996, 14:303-7. 10.1016\/0887-8994(96)00052-5","journal-title":"Pediatr Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/adc.71.2.153","article-title":"Bone marrow suppression induced by high dose valproic acid","volume":"71","author":"Kishi T","year":"1994","unstructured":"Kishi T, Fujita N, Kawaguchi H, Ishimae M, Watanabe K, Tanaka T. Bone marrow suppression induced by high dose valproic acid. Arch Dis Child. 1994, 71:153-5. 10.1136\/adc.71.2.153","journal-title":"Arch Dis Child"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200001000-00012","article-title":"Hematologic toxicity of sodium valproate","volume":"22","author":"Acharya S","year":"2000","unstructured":"Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000, 22:62-5. 10.1097\/00043426-200001000-00012","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C381","article-title":"Valproic acid-induced neutropenia","volume":"37","author":"Vesta KS","year":"2003","unstructured":"Vesta KS, Medina PJ. Valproic acid-induced neutropenia. Ann Pharmacother. 2003, 37:819-21. 10.1345\/aph.1C381","journal-title":"Ann Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/44750-severe-pancytopenia-induced-by-valproic-acid","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:19:40Z","timestamp":1707488380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/44750-severe-pancytopenia-induced-by-valproic-acid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.11252","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}